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INTRODUCTION 
Risk prediction in the practice of medical genetics is 
probabilistic and not absolute.  The complexity of risk 
predictions is increased by the complexity of systems biology 
and an incomplete understanding of genetic and environmental 
modifiers.  Genotype does not predict phenotype even for rare 
“single” gene or “simple” Mendelian disorders.  The challenges 
facing risk assessment in the medical context include lack of 
understanding of the complexity of common, complex disorders, 
the influence of genetic and environmental effects in 
pharmacogenetics, and the difficulty of whole genome 
approaches.  The inability to give absolutes to our patients 
means that often we give misinformation to our patients.  This 
article discusses how risk predictions in the genetics context 
are compounded by complexity and incompleteness in our 
understanding of systems biology. 
GENETICS AND RISK PREDICTION 
Genotype1 cannot necessarily predict phenotype2 for rare 
“single” gene disorders3 due to the complexity of the genome,4 
the proteome5 interacting with the transcriptome,6 and the 
dynamically coupled systems that are involved.  Beyond the 
rare single gene disorders are common “complex” disorders, 
which occur when the primary mutated gene effect diminishes 
and two or more mutated genes have co-equal effects.  Familiar 
examples of complex disorders include obesity, heart disease, 
diabetes, and cancer.  Examining and predicting complex traits 
is even more complicated than single gene traits, and poses the 
 1. Genotype is the genetic makeup of an individual.  SCIENCE AND 
TECHNOLOGY ENCYCLOPEDIA 231 (2000). 
 2. Phenotype is the physical characteristics of an individual resulting 
from heredity.  SCIENCE AND TECHNOLOGY ENCYCLOPEDIA, supra note 1, at 
400. 
 3. A single gene disorder is a genetic disorder caused by one gene.  The 
Human Genome, http://genome.wellcome.ac.uk (last visited Mar. 28, 2007). 
 4. The genome is the entire complement of genetic material of an 
individual coded in sequence by the DNA that makes up the chromosomes.  
SCIENCE AND TECHNOLOGY ENCYCLOPEDIA, supra note 1, at 231. 
 5. The proteome is the entire complement of proteins in a given 
biological organism or system.  TOM STRACHAN & ANDREW P. READ, HUMAN 
MOLECULAR GENETICS 3 553 (Garland Sci. 2004) (1996). 
 6. The transcriptome is the set of all messenger ribonucleic acid (mRNA) 
molecules in a cell or set of cells.  STRACHAN & READ, supra note 5, at 545. 
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question of how to deal with them in providing medical care.7  
Despite their differences, however, common complex disorders 
are not distinct from their rare single gene counterparts; both 
are part of a continuum of increasing structural complexity.  
Therefore, the tools developed for “single” gene disorders will be 
adaptable to common complex diseases.  Yet, some of the 
challenges with common complex traits stem from the fact that 
we do not understand the predictive significance of either the 
genetics or the environment at this point. 
Consider risk prediction for cystic fibrosis (CF).  CF is an 
autosomal recessive multisystem disease which can affect the 
lungs, liver, pancreas, small intestine, reproductive tract, and 
sweat glands of the skin.8  CF is considered to be a single gene 
disorder caused by mutations in the cystic fibrosis conductance 
regulator (CFTR) chloride channel, which is encoded on 
chromosome seven.9  Lung disease is the leading cause of death 
for patients with CF.10  Thick mucus clogs the air passages of 
the lungs and these clogged passages lead to chronic 
respiratory infections and progressive destruction of the 
lungs.11  Mucus can also obstruct the pancreatic ducts, which 
prevents digestive enzymes from entering the intestines, 
eventually leading to loss of insulin production and diabetes 
mellitus.12  Research suggests a complexity of CFTR regulation 
based on post-translational modification, protein kinases A and 
C, and the availability of adenosine triphosphate (ATP).13 
The most common CFTR mutation in Caucasians is 
 7. Common complex diseases involve multiple genes and gene and 
environment interactions, making diagnosis more difficult.  Lori B. Andrews & 
Erin Shaughnessy Zuiker, Ethical, Legal and Social Issues in Genetic Testing 
for Complex Genetic Diseases, 37 VAL. U. L. REV. 793, 795 (2003). 
 8. See Francis S. Collins, Cystic Fibrosis: Molecular Biology and 
Therapeutic Implications, 256 SCIENCE 774, 774 (1992). 
 9. See Collins, supra note 8, at 774. 
 10. See Am. Lung Ass’n, Cystic Fibrosis Fact Sheet, Nov. 2006, 
http://www.lungusa.org/site/pp.asp?c=dvLUK9O0E&b=35042 (indicating that 
respiratory failure is the “primary cause” of death for 90% of adults with CF). 
 11. See id. 
 12. See Paulus Ripa et al., The Relationship Between Insulin Secretion, the 
Insulin-Like Growth Factor Axis and Growth in Children with Cystic Fibrosis, 
56 CLINICAL ENDOCRINOLOGY 383 (2002). 
 13. For an extensive survey of research on the relationships between 
CFTR functioning and translational modification, protein kinase, and ATP 
levels, see generally Nat’l Ctr. for Biotech Info., Online Mendelian Inheritance 
in Man, Cystic Fibrosis Transmembrane Conductance Regulator; CFTR, 
www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=602421 (last visited Mar. 28, 
2007). 
MCCABE E & MCCABE L. Genomic Medicine: A Future Flooded with Risk Information. MINN. 
J.L. SCI. & TECH. 2007;8(2):429-439. 
432 MINN. J. L. SCI. & TECH. [Vol. 8:2 
 
                                                          
 
∆F508.14  Originally, data suggested that ∆F508 was associated 
with the most serious pulmonary symptoms, although this 
putative association has not been supported by further research 
based on information obtained from an increased numbers of 
patients.15  There is a lack of genotype-phenotype correlation, 
and modifier genes determine the severity of ∆F508 
homozygosity.16  Drumm et al. studied the sequence variants in 
ten genes previously reported to be modifiers of CF in patients 
separated into groups with severe or mild lung disease.17  
Among the ten genes investigated they found significant 
associations only for transforming growth factor β1 (TGFβ1).18  
TGFβ1 is involved in cell signaling and gene expression.19  The 
functions of TGFβ1 include immune responses, 
proinflammatory and anti-inflammatory effects, growth and 
differentiation, and extracellular matrix production.20  TGFβ1 
is also associated with other forms of lung disease, including 
the progression of idiopathic pulmonary fibrosis, chronic 
obstructive pulmonary disease, and asthma.21  Drumm et al. 
identified thirty-one additional markers, referred to as single 
nucleotide polymorphisms (SNPs), around TGFβ1, and the 
association between disease severity and TGFβ1 SNP variants 
was confirmed. 22  Increased levels of the TGFβ1 protein were 
 14. Anselm A. Zdebik et al., Additional Disruption of the C1C-2 C1– 
Channel Does Not Exacerbate the Cystic Fibrosis Phenotype of Cystic Fibrosis 
Transmembrane Conductance Regulator Mouse Models, 279 J. BIOLOGICAL 
CHEMISTRY 22276 (2004). 
 15. See, e.g., Joseph Zabner et al., CFTR ∆F508 Mutation Has Minimal 
Effect on the Gene Expression Profile of Differentiated Human Airway 
Epithelia, 289 AM. J. PHYSIOLOGY - LUNG CELLULAR & MOLECULAR 
PHYSIOLOGY L545 (2005), available at 
http://ajplung.physiology.org/cgi/reprint/289/4/L545.  
 16. See, e.g., Mitchell L. Drumm et al., Genetic Modifiers of Lung Disease 
in Cystic Fibrosis, 353 NEW ENG. J. MED. 1443, 1449-53 (2005). 
 17. Drumm et al. split a population of over eight hundred Delta F508 
positive patients into two groups based upon the severity of their lung disease 
symptoms.  Id. at 1444.  The first group belonged in the top quartile of 
severity, while the second group represented the bottom quartile of severity.  
Id.  Drumm et al. then looked at variance of ten genes that allegedly 
influenced the severity of CF and compared those results between these two 
groups with the severe and mild lung disease.  Id. at 1444-45. 
 18. Id. at 1446-48. 
 19. See id. at 1451. 
 20. Id. at 1451. 
 21. Id. 
 22. Id. at 1448-49. 
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associated with more severe lung disease.23 
Research has also found that TGFβ1 reduces CFTR 
expression in nasal polyps in patients who do not have cystic 
fibrosis.24  In 2005, a group from Spain headed by Virginie 
Prulière-Escabasse furthered earlier work with TGFβ1, looking 
at the connection between CF and nasal polyposis.  Nasal 
polyposis is a chronic inflammatory disease of the nasal mucosa 
causing polyps in the nose and sinuses.25  It can be primary, 
meaning we do not know what it is associated with, but it also 
has 50% prevalence with CF.26  The hypothesis of Prulière-
Escabasse et al. was that altered CFTR expression and function 
was involved in the pathogenesis of nasal polyposis.27  They 
looked only at CFTR expression in non-CF patients and 
compared the nasal polyp to the control mucosal epithelial 
cells, finding that CFTR was expressed in the controlled nasal 
epithelial cells but not in the nasal polyps.28  Thus, TGFβ1 
down-regulated CFTR expression and function measured by 
chloride currents in the control but not the nasal polyps.29  
From this finding, they concluded that this was consistent with 
studies in CF patients that showed high TGFβ1 secretors had 
more severe lung disease.30  These results are consistent with 
another study that found that patients with CF who secreted 
high levels of TGFβ1 had more severe lung disease.31  Based on 
these similar findings, there may be a story developing for 
TGFβ1 as a genetic modifier.  The research has found that 
TGFβ1 functions in immune responses,32 it has both 
 23. See id. at 1449-51. 
 24. Virginie Prulière-Escabasse et al., TGF- β1 Downregulates CFTR 
Expression and Function in Nasal Polyps of Non-CF Patients, 288 AM. J. OF 
PHYSIOLOGY - LUNG CELLULAR & MOLECULAR PHYSIOLOGY L77 (2005), 
available at http://ajplung.physiology.org/cgi/reprint/288/1/L77 (comparing 
CFTR expression in nasal polyps to normal mucosa in the same individual and 
finding that CFTR is expressed in normal mucosa, but not in the nasal 
polyps). 
 25. Id. at L77. 
 26. Id. 
 27. Id. 
 28. Id. at L78-L79, L81. 
 29. Id 
 30. Id. at L82. 
 31. Peter D. Arkwright et al., TGF- β1 Genotype and Accelerated Decline in 
Lung Function of Patients with Cystic Fibrosis, 55 THORAX 459 (2000), 
available at http://thorax.bmj.com/cgi/reprint/55/6/459. 
 32. See, e.g., S. Kakumu et al., Effect of Recombinant Human 
Transforming Growth Factor β1on Immune Responses in Patients with 
Chronic Hepatitis B, 13 LIVER 62 (1993). 
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pro-inflammatory and anti-inflammatory effects,33 it is 
involved in growth and differentiation,34 and it is involved in 
extra-cellular matrix production.35  In lung disease it has been 
shown to be associated with progression of idiopathic 
pulmonary fibrosis,36 increased activity, chronic obstructive 
pulmonary disease,37 and asthma.38  We have more work to do, 
however, to confirm that there is a real biological relationship. 
THE COMPLEXITY OF SYSTEMS BIOLOGY 
Risk predictions are compounded by the complexity of 
systems biology.39  Systems biologists would argue that these 
dynamic systems can be modeled and the models are amenable 
to mathematical analyses, moving biology from a descriptive 
science to a quantitative discipline.  In the twentieth century, 
physics developed the fundamental scientific basis for rigorous 
applications in engineering by using mathematics.  In the 
twenty-first century, biology will provide the foundation for 
applications in medicine, and these applications will 
increasingly rely on the mathematical algorithms of systems 
biology. 
Medicine has begun to rely on mathematical algorithms in 
ways that are transparent to both physician and patient.  For 
example, in the field of imaging, X-rays are no longer analogue, 
which involves direct film exposure, but are now digital, and 
the images, including sharpness and contrast, are based on 
 33. See Sharon M. Wahl, Transforming Growth Factor Beta (TGF-β) in 
Inflammation: A Cause and a Cure, 12 J. CLINICAL IMMUNOLOGY 61 (1992). 
 34. See Mary E. Dickinson et al., Chromosomal Localization of Seven 
Members of the Murine TGF-β Superfamily Suggests Close Linkage to Several 
Morphogenetic Mutant Loci, 6 GENOMICS 505 (1990). 
 35. See Chie-Pein Chen et al., Hypoxia and Transforming Growth Factor-
β1 Act Independently to Increase Extracellular Matrix Production by Placental 
Fibroblasts, 90 J. CLINICAL ENDOCRINOLOGY & METABOLISM 1083 (2005). 
 36. See Moira K.B. Whyte, Genetic Factors in Idiopathic Pulmonary 
Fibrosis: Transforming Growth Factor-β Implicated at Last, 168 AM. J. OF 
RESPIRATORY & CRITICAL CARE MED. 410 (2003). 
 37. See L. Wu et al., Transforming Growth Factor-β1 Genotype and 
Susceptibility to Chronic Obstructive Pulmonary Disease, 59 THORAX 126 
(2004). 
 38. See Judith C.W. Mak et al., Analysis of TGF- β1 Gene Polymorphisms 
in Hong Kong Chinese Patients with Asthma, 117 J. ALLERGY CLINICAL 
IMMUNOLOGY 92 (2006). 
 39. Systems biology is the study of the relationships and interactions 
between and among parts of biological systems.  Ekat Kritikou, Forward, All 
Systems Go!, 7 NATURES REVS. MOLECULAR CELL BIOLOGY 801, 801 (2006). 
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calculations from the raw digital data.40  Mathematical 
algorithms are also crucial for ultrasonography, computerized 
tomography (CT), magnetic resonance imaging (MRI), and 
positron emission tomography (PET).  These algorithms are 
invisible to the physician, and a physician need not be a 
mathematician to examine a digital image. 
Systems dynamics are based on network architecture.41  
We used to think that biology was composed of random 
networks, in which every node was connected to a similar 
number of nodes.42  However, biology is made up of scale-free 
networks in which some nodes are more highly connected, 
while others may have only one connection, a structure 
described as “hub and spoke.”  If a node that is a hub does not 
function because of a mutation, then this takes out a significant 
portion of the network.  If a node with only one connection does 
not function, however, the network is not affected as much, or 
perhaps not at all.  The internet is an example of a scale-free 
network comprised of interconnected nodes.  A number of these 
nodes are highly connected; these are the critical servers.  
Other nodes have just one connection, such as a desktop 
computer or laptop device.  If one computer stops working, it 
will not affect the network.  If a server node at a major 
university goes down, all of the associated computers can no 
longer access the other nodes, and are rendered useless for 
networking purposes at that time. 
Our knowledge of modifiers is incomplete.  If we look at 
cystic fibrosis we know about genetic modifiers, such as TGFβ1, 
and environmental modifiers, such as colonization with 
Pseudomonas bacteria.  These individual modifiers will 
influence risk in a probabilistic manner.  However, risk 
influences will vary depending upon the genetic make-up of the 
individual.  Therefore, to better understand the probabilistic 
risks associated with a particular individual, we will need 
whole genome information on large populations. 
 40. H.K. Huang et al., Digital Radiology at the University of California, 
Los Angeles: A Feasibility Study, 16 J. DIGITAL IMAGING (2003). 
 41. See Albert-László Barabási & Zoltán N. Oltvai, Network Biology: 
Understanding the Cell’s Functional Organization, 5 NATURE REVIEWS 
GENETICS 101 (2004) (discussing a parallel between cellular function and 
architectural features of other complex systems). 
 42. Id. at 104. 
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PHARMACOGENETICS: AT THE INTERFACE OF 
GENETICS AND ENVIRONMENT 
Pharmacogenomics, the interface of genetics and 
environment, is one of the first places where genomic medicine 
is beginning to impact routine medical care.43  This is the case 
for molecular microbiology in particular, dealing with viruses 
and bacteria for rapid diagnosis.  The incidence of adverse drug 
reactions (ADRs) in U.S. hospitals is 6.7%, and the incidence of 
fatal ADRs is 0.3%.44  Many drug side effects are not stochastic 
events, because individuals are genetically predisposed to 
experience an ADR.45  The physician’s goal is to use 
pharmacogenetics to predict and prevent ADRs and to optimize 
an individual’s therapy. 
Genomic medicine will be predictive, preventive, and 
personalized.  Testing devices will be required to acquire 
genomic information in order to utilize pharmacogenomics.  
The first microarray-based46 testing device that was approved 
by the Food and Drug Administration (FDA) on January 12, 
2005 was the Roche AmpliChip CYP450.47  The AmpliChip 
CYP450 tests for genetic variation in the cytochrome P450 
enzymes, CYP2D6 and CYP2C19, which metabolize drugs.48  
Drugs which impact these enzymes include the following 
classes: anti-depressants, anti-psychotics, anticonvulsants, 
cardiovascular medications, cancer chemotherapeutics, and 
anti-malarial drugs.49  Physicians typically give the same dose 
to all adults, assuming identical drug metabolism in all adults. 
 43. Pharmacogenomics is the study of how genes modify drug metabolism.  
STRACHAN & READ, supra note 6, at 610. 
 44. Jason Lazarou, et al., Incidence of Adverse Drug Reactions in 
Hospitalized Patients, 279 J. AM. MED. ASS’N 1200 (1998). 
 45. Taisei Mushiroda et al., A Model of Prediction System for Adverse 
Cardiovascular Reactions by Calcineurin Inhibitors Among Patients with 
Renal Transplants Using Gene-Based Single-Nucleotide Polymorphisms, 50 J. 
HUM. GENETICS 442 (2005). 
 46. A DNA microarray is a two-dimensional array of genes or gene 
fragments set on a solid surface, such as glass, plastic or silicon chip for use in 
monitoring gene expression levels.  STRACHAN & READ, supra note 6, at 175. 
 47. Press Release, F. Hoffman-La Roche Ltd., Roche’s AmpliChip CYP450 
Test Receives FDA Clearance-Microarray-Based Diagnostic Test. (Jan. 12, 
2005), in Medical News Today, available at 
medicalnewstoday.com/medicalnews.php?newsid=18822. 
 48. Li Li et al., New Cytochrome P4250 2D6*56 Allele Identified by 
Genotype/Phenotype Analysis of Cryopreserved Human Hepatocytes, 34 DRUG 
METABOLISM & DISPOSITION 1411 (2006). 
 49. Press Release, supra note 47. 
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The AmpliChip CYP450 identifies different rates of 
metabolism and classifies people as poor, intermediate, normal, 
and ultra-rapid metabolizers.50  Poor metabolizers suffer the 
effects of toxic drug levels from prolonged and/or excessive drug 
levels.  Ultra-rapid metabolizers may not achieve any benefit 
from a drug because they break down the drug before it has 
time to work.  The opposite phenomenon occurs for pro-drugs 
that are metabolized to the therapeutically active compound. 
WHOLE GENOME APPROACHES 
The same kind of technology that is used for the 
Cytochrome P450, the AmpliChip, can also be used for 
whole-genome approaches.  Whole genome applications 
currently use SNP microarrays or SNP chips.51  SNPs (for 
example, where a base A is changed to a C), usually occur in a 
non-coding region that does not make a difference.52  It may be 
in a site that does not change to an amino acid.  An SNP is not 
a mutation, but a genetic marker.  SNPs are distributed 
throughout the genome, and SNP chips were originally 
designed to identify SNP variation associated with different 
phenotypes.  SNP chips can also be used to look at the 
presence, absence or amplification of a genomic region.  SNP 
chips combine molecular cytogenetics with the identification of 
modifiers so that SNPs influencing the location of a mutation in 
the DNA of an individual or a deletion in the DNA of an 
individual can be examined. 
We have been using SNP chips to screen for individuals 
with the chromosome 22q11.2 deletion syndrome.53  This 
syndrome may include congenital cardiovascular defects, 
craniofacial abnormalities, and hypoplasia of the thymus and 
parathyroid glands.54  This is the most frequent interstitial 
deletion in humans – one in 4,000 live births –  and 90% of 
affected individuals have a three megabase region deleted.55  
This disorder shows a lack of genotype/phenotype correlation, 
 50. Id. 
 51. Itsik Pe’er et al., Evaluating and Improving Power in Whole-Genome 
Association Studies Using Fixed Marker Sets,  38 NATURE GENETICS 663 
(2006). 
 52. Id. 
 53. C.M. Stanczak et al., Single Chromosomal Copy Deletion in Digeorge 
Syndrome Using a SNP Mapping Array, __HUMAN MUTATION__ (forthcoming 
2007). 
 54. Id. 
 55. Id. 
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meaning that patients with identical deletions have different 
phenotypes, and patients with different deletions have identical 
phenotypes.  We have successfully used SNP chips to identify 
patient deletions.  Combining information about the deletion 
with whole-genome SNP variation will enable us to improve 
prediction of phenotype.  However, risk predictions will remain 
probabilistic and not absolute. 
With a whole-genome approach, as an example, we can 
identify patients’ deletions.  This can be combined with the 
knowledge of these polymorphisms, the SNPs in the deleted 
region and genome-wide.  We can utilize whole-genome 
information to improve prediction of the phenotype, that is, all 
other SNPs.  Despite all of this, risk predictions are still going 
to be probabilistic and not absolute.  It is just the way biology 
is. 
UNDERSTANDING AND UTILIZING COMPLEXITY 
In order to understand and utilize complexity we need 
systems biology.  Systems biology is an attempt to quantify the 
complexity of dynamically coupled robust networks.  At this 
time, however, we have limited information and methods; much 
remains unknown.  Systems biology will involve an incredible 
volume of data and corresponding mathematical algorithms for 
analysis.  Despite the mathematical reduction of data, the 
output will be voluminous.  We need to find a way to represent 
the output and the risks by genomic position or network 
diagrams that physicians can easily interpret and patients can 
easily understand. 
CONCLUSION 
Genomic medicine represents a future flooded with risk 
information.  We already recognize that we do not know all of 
the information needed to counsel our patients in the genetics 
clinic because this risk information is inherently probabilistic 
and not absolute.  We must develop comprehensive 
representations of this risk information in order to better 
transfer that information to the general pediatrician and the 
general practitioner for both the care of their patients and for 
informing their patients.  In pediatrics, parents tell us they do 
not want a physician to dictate the care of their child, but want 
to be partners in the care of their child.  Parents want to 
understand what this risk information means.  Developing 
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comprehensive representations of risk information will require 
multi-disciplinary teams of geneticists, mathematicians, 
engineers, and others to work together. 
